Latest Us Market News

Amaero Ltd has amended its scheme implementation deed, revising the consideration offered to option holders as it progresses with its re-domiciliation from Australia to the US. Key milestones for the transition are scheduled through mid-2026.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Enlitic has secured a $1.5 million contract to migrate over 71 million clinical files for Penn Medicine Doylestown Health, reinforcing its foothold in the US healthcare IT sector.

Sultan Resources is advancing plans to list on the US OTC Markets Group, aiming to enhance liquidity and attract North American investors while pursuing strategic acquisitions.

Eden Innovations reports a robust 65% increase in US OptiBlend revenue for FY2026 to date, driven by rising demand from data centres seeking cost-effective, lower-emission backup power solutions.

OD6 Metals has significantly expanded its claim holdings around the Quinn Fluorspar Project in Nevada, securing promising new exploration targets including the large Dresser epithermal alteration zone. This move strengthens its position in a critical mineral district vital to US supply chains.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

iCandy Interactive is exploring a US listing for its subsidiary Lemon Sky Studios to unlock shareholder value, while facing a likely ASX delisting due to audit delays. The company also plans a capital raise to support these initiatives.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

Titomic Limited is planning to redomicile from Australia to the United States, aiming to deepen its footprint in the US defense and aerospace sectors and pursue a US stock exchange listing.